

Nur für Forschungszwecke

# TGFBI / BIGH3 Polyklonaler Antikörper



Katalog-Nr.: 10188-1-AP

Vorgestelltes Produkt

60 Publikationen

## Allgemeine Informationen

<b>Katalog-Nr.:</b> 10188-1-AP	<b>GenBank-Zugangsnummer:</b> BC000097	<b>Reinigungsmethode:</b> Antigen-Affinitätsreinigung
<b>Größe:</b> 150ul, Konzentration: 550 µg/ml von Nanodrop;	<b>GeneID (NCBI):</b> 7045	<b>Empfohlene Verdünnungen:</b> WB 1:1000-1:4000 IP 0.5-4.0 µg für IP und 1:200-1:1000 für WB
<b>Wirt:</b> Kaninchen	<b>Vollständiger Name:</b> transforming growth factor, beta-induced, 68kDa	<b>IHC 1:50-1:500</b> <b>IF 1:200-1:800</b>
<b>Isotyp:</b> IgG	<b>Berechnete Masse:</b> 683 aa, 75 kDa	
<b>Immunogen Katalognummer:</b> AG0241	<b>Beobachtete Masse:</b> 64 kDa	

## Anwendungen

**Geprüfte Anwendungen:**  
FC, IF, IHC, IP, WB, ELISA

**In Publikationen genannte Anwendungen:**  
IF, IHC, IP, Neutralization, WB

**Getestete Reaktivität:**  
Human, Maus, Ratte

**Zitierte Arten:**  
Human, Maus, Ratte

**Hinweis-IHC: Antigenmaskierung mit TE-Puffer pH 9,0 empfohlen. (\*) Wahlweise kann die Antigenmaskierung auch mit Citratpuffer pH 6,0 erfolgen.**

### Positivkontrollen:

**WB:** Maus-Augengewebe, HeLa-Zellen, humanes Nierengewebe, Mauslebergewebe, Y79-Zellen

**IP:** HeLa-Zellen,

**IHC:** humanes Nierengewebe, humanes Leberkarzinomgewebe, Maus-Augengewebe

**IF:** mit TGF-beta-1 behandelte A549-Zellen,

## Hintergrundinformationen

TGFBI, also named as BIGH3, Kerato-epithelin and RGD-CAP, binds to type I, II, and IV collagens. TGFBI is an adhesion protein which may play an important role in cell-collagen interactions. In cartilage, it may be involved in endochondral bone formation. TGFBI is an extracellular matrix adaptor protein, it has been reported to be differentially expressed in transformed tissues. TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy. (PMID:20509890) Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD). Defects in TGFBI are the cause of corneal dystrophy Groenouuw type 1 (CDGG1). Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1). Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB). Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB). Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A). Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD).

## Bemerkenswerte Veröffentlichungen

Verfasser	Pubmed ID	Journal	Anwendung
Nobuhiro Nakazawa	31571056	Ann Surg Oncol	IHC
Nathalie Allaman-Pillet	26387839	Exp Eye Res	WB, IF
Taku Sato	30156359	Cancer Sci	WB, IHC

## Lagerung

### Lagerungsbedingungen:

Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil

### Lagerungspuffer:

PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.

Aliquotieren ist nicht notwendig bei -20°C Lagerung

**\*\*\* 20ul-Größen enthalten 0.1% BSA**


For technical support and original validation data for this product please contact:

T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free in USA), or 1(312) 455-8498 (outside USA)


E: proteintech@ptglab.com  
W: ptglab.com

**This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.**


## Ausgewählte Validierungsdaten




Mouse eye tissue were subjected to SDS PAGE followed by western blot with 10188-1-AP (TGFBI / BIGH3 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.




WB result of TGFBI / BIGH3 antibody (10188-1-AP; 1:300; incubated at room temperature for 1.5 hours) with sh-Control and sh-TGFBI / BIGH3 transfected HeLa cells.




Immunohistochemical analysis of paraffin-embedded human kidney using 10188-1-AP (TGFBI / BIGH3 antibody) at dilution of 1:100 (under 10x lens).




Immunohistochemical analysis of paraffin-embedded human kidney using 10188-1-AP (TGFBI / BIGH3 antibody) at dilution of 1:100 (under 40x lens).



Immunofluorescent analysis of (-20°C Methanol) fixed A549 cells, untreated (left) or TGF-β-treated (right), using TGFBI / BIGH3 antibody (10188-1-AP) at dilution of 1:400 and CoraLite® 488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).



1X10<sup>6</sup> Y79 cells were intracellularly stained with 0.4 ug Anti-Human TGFBI / BIGH3 (10188-1-AP) and CoraLite® 488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).



IP Result of anti-TGFBI / BIGH3 (IP:10188-1-AP, 3ug; Detection:10188-1-AP 1:300) with HeLa cells lysate 1000ug.